Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy

Thomas, E. Donnall; Lochte, H. L.; Wan, Lu; Ferrebee, Joseph W.

doi:10.1056/nejm195709122571102

Cited by 995 publications

(491 citation statements)

References 15 publications

Supporting

Mentioning

455

Contrasting

Unclassified

Order By: Relevance

“…Each send-out, from Spring 1996 to Autumn 2004 was chronologically assigned with a unique number (i.e., [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. In this way, we analyzed any effect of the EQA program on the results of the participants as a function of time.…”

Section: Data Processing and Parameter Classificationmentioning

confidence: 99%

See 1 more Smart Citation

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Levering

Preijers

Wieringen

et al. 2007

Cytometry Part B Clinical

View full text Add to dashboard Cite

Background: A biannual external quality assurance (EQA) scheme for flow cytometric CD34+ haematopoietic stem cell enumeration has been operational in the Benelux countries since 1996. In an evaluation of the results of 16 send-outs, we studied the effects of the methods used on assay outcome and whether or not this exercise was effective in reducing between-laboratory variation.Methods: Data were analyzed using robust multivariate regression. This approach is relatively insensitive to outliers and is used to assess the effect of methodological aspects of CD34+ cell counting on the bias and variability.Results: Five variables were associated with significant bias of absolute CD34+ cell counts: (i) unique laboratory number (ULN), (ii) gating strategy; (iii) CD34 mAb fluorochrome; (iv) type of flow cytometer, and (v) method of sample preparation. In addition, ULN and platform methodology (i.e., single vs. dual) contributed significantly to the variability of this assay. Overall, the variability in results of CD34+ cell enumeration has declined with time; in particular, after a practical workshop in which participants were trained to use the ''single platform ISHAGE protocol.'' Conclusions: Between-laboratory variation in CD34+ cell enumeration can be reduced by standardization of methodologies between centres. Our approach, i.e., EQA with targeted training and feedback in response to reported results, has been successful in reducing the variability of CD34+ cell enumeration between participants. q 2007 Clinical Cytometry Society

show abstract

Section: Data Processing and Parameter Classificationmentioning

confidence: 99%

“…Haematopoietic stem cell (HSC) transplantation has been successfully used to reconstitute hematopoiesis after myeloablative therapies in man since the late 1950s (1,2). HSCs have the capability of homing into the marrow microenvironment and regenerating multi-lineage haematopoiesis in relatively short time (3).…”

mentioning

confidence: 99%

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Levering

Preijers

Wieringen

et al. 2007

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

“…In the mid 1950s it was discovered that haematopoietic stem cells were responsible for this protection (Storb, 2003). These findings led to more research and the possibility of treating patients with haematological malignancies, and in 1957 the first successful HSCT in a human was performed (Thomas et al, 1957). A patient suffering from end stage leukaemia was treated with lethal doses of irradiation and given bone marrow from a sibling intravenously.…”

Section: History Indications and Volumementioning

confidence: 99%

Having a sibling as donor: Patients' experiences immediately before allogeneic hematopoietic stem cell transplantation

Kisch

Bolmsjö

Lenhoff

et al. 2014

European Journal of Oncology Nursing

View full text Add to dashboard Cite

“…The first allogeneic HSCT was tested in 1957 in a pioneering paper by Thomas et al [13]. They reported six leukemic patients treated with total body irradiation (TBI) and chemotherapy with subsequent intravenous infusion of marrow from a normal donor.…”

Section: The Early Daysmentioning

confidence: 99%

Advances in Hematopoietic Stem Cell Transplantation

Alvarez-Silva¹

2017

Adv Tech Biol Med

View full text Add to dashboard Cite

Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy

Cited by 995 publications

References 15 publications

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries

Having a sibling as donor: Patients' experiences immediately before allogeneic hematopoietic stem cell transplantation

Advances in Hematopoietic Stem Cell Transplantation

Contact Info

Product

Resources

About